Cadrenal Therapeutics files ATM prospectus supplement for up to 2.17M shares; $7.7M already sold

Cadrenal Therapeutics, Inc.

Filed prospectus supplement to sell up to 2,169,272 shares of common stock via ATM program with H.C. Wainwright.
Company had sold $7,655,240 in common stock under the existing ATM agreement as of the filing date.
Wainwright earns 3.0% commission on gross proceeds from any sales under the ATM agreement.
Company may suspend or terminate the offering at any time; no obligation to sell shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.